The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease

REFERENCES

• Bell S., Kamm M. A. Antibodies to tumor necrosis factor-alpha as treatment for Crohn's disease. Lancet 2000; 355: 858–860
   PubMed Web of Science ®Google Scholar
• Cabot P. J. Immune-derived opioids and peripheral antinociception. Clin. Exp. Pharmacol. Physiol. 2001; 28: 230–232
   PubMed Web of Science ®Google Scholar
• Chen Y. L., Law P. Y., Loh H. H. Nuclear factor-κ B signaling in opioid functions and receptor gene function. J. Neuroimmun. Pharmacol 2006; 1: 270–279
   PubMedGoogle Scholar
• Cominelli F. Cytokine-based therapies for Crohn's disease—new paradigms. New Engl. J. Med. 2004; 351: 2045–2048
   PubMed Web of Science ®Google Scholar
• Efanov A. M., Koshkin A. A., Sazanov L. A., Borodulina O. I., Varfolomeev S. D., Zaitsev S. V. Inhibition of the respiratory burst in mouse macrophages by ultra-low doses of an opioid peptide is consistent with a possible adaptation mechanism. FEBS Lett. 1994; 355: 114–116
   PubMedGoogle Scholar
• Greeneltch K. M., Haudenschild C. C., Keegan A. D., Shi Y. The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-α production. Brain Behav. Immun. 2004; 18: 476–484
   PubMedGoogle Scholar
• Hanauer S. B. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk?. Gut 2007; 56: 1181–1183
   PubMed Web of Science ®Google Scholar
• Hanauer S. B., Present D. H. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 2003; 3: 81–92
   PubMedGoogle Scholar
• Hook S., Camberis M., Prout M., Le Gros G. Absence of pre-proenkephalin increases the threshold for T-cell activation. J. Neuroimmunol. 2003; 140: 61–68
   PubMedGoogle Scholar
• House R. V., Thomas P. T., Bhargava H. N. A comparative study of immunomodu-lation produced by in vitro exposure to δ opioid receptor agonist peptides. Peptides 1996; 17: 75–81
   PubMed Web of Science ®Google Scholar
• Hucklebridge F. H., Hudspith B. N., Lydyard P. M., Brostoff J. Stimulation of human peripheral lymphocytes by methionine enkephalin and δ -selective opioid analogues. Immunopharmacology 1990; 19: 87–91
   PubMedGoogle Scholar
• Jimenez N., Puig M. M., Pol O. Anti-exudative effects of opioids and expression of κ - and δ -opioid receptors during intestinal inflammation in mice: Involvement of nitric oxide. J. Pharmacol. Exp. Ther. 2006; 316: 261–270
   PubMedGoogle Scholar
• Kamm M. A. Review article: Biological drugs in Crohn's disease. Aliment. Pharmacol. Ther. 2006; 24(S3)80–89
   PubMedGoogle Scholar
• Kamphuis S., Eriksson F., Kavelaars A., Zijlstra J., van de Pol M., Kuis W., Heijnen C. J. Role of endogenous pro-enkephalin A-derived peptides in human T-cell proliferation and monocyte IL-6 production. J. Neuroimmunol. 1998; 84: 53–60
   PubMedGoogle Scholar
• Kandiel A., Fraser A. G., Korelitz B. I., Brensinger C., Lewis J. D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121–1125
   PubMed Web of Science ®Google Scholar
• Keane J., Gershon S., Wise R. P., Mirabile-Levens E., Kasznica J., Schwieterman W. D., Siegel J. N., Braun M. M. Tuberculosis associated with infliximab, a tumor necrosis factor-α -neutralizing agent. New Engl. J. Med. 2001; 345: 1098–1104
   PubMed Web of Science ®Google Scholar
• Li G., Cui G., Tzeng N. S., Wei S. J., Wang T., Block M. L., Hong J. S. Femto-molar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J. 2005; 19: 489–496
   PubMedGoogle Scholar
• Liu Y., Qin L., Li G., Zhang W., An L., Liu B., Hong J. S. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 2003; 305: 212–218
   PubMed Web of Science ®Google Scholar
• McCarthy L., Wetzel M., Sliker J. K., Eisenstein T. K., Rogers T. J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001; 62: 111–123
   PubMed Web of Science ®Google Scholar
• Mudter J., Weigmann B., Bartsch B., Kiesslich R., Strand D., Galle P. R., Lehr H. A., Schmidt J., Neurath M. F. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am. J. Gastroenterol. 2005; 100: 64–72
   PubMed Web of Science ®Google Scholar
• Murthy S. N., Cooper H. S., Shim H., Shah R. S., Ibrahim S. A., Sedergran D. J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig. Dis. Sci. 1993; 38: 1722–1734
   PubMed Web of Science ®Google Scholar
• Navarro F., Hanauer S. B. Treatment of inflammatory bowel disease: Safety and tolerability issues. Am. J. Gastroenterol. 2003; 98: S18–S23
   PubMed Web of Science ®Google Scholar
• Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694–702
   PubMed Web of Science ®Google Scholar
• Petrakis I., Ralevski E., Nich C., Levinson C., Carroll K., Poling J., Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J. Clin. Psychopharmacol. 2007; 27: 160–165
   PubMed Web of Science ®Google Scholar
• Philippe D., Chakass D., Thuru X., Zerbib P., Tsicopoulos A., Geboes K., Bulois P., Breisse M., Vorng H., Gay J., Colombel J. F., Desreumaux P., Chamaillard M. μ -Opioid receptor expression is increased in inflammatory bowel diseases: Implications for homeostatic intestinal inflammation. Gut 2006; 55: 815–823
   PubMedGoogle Scholar
• Philippe D., Dubuquoy L., Groux H., Brun V., Chuoi-Mariot M. T., Gaveriaux-Ruff C., Colombel J. F., Kieffer B. L., Desreumaux P. Anti-inflammatory properties of the μ opioid receptor support its use in the treatment of colon inflammation. J. Clin. Invest. 2003; 111: 1329–1338
   PubMed Web of Science ®Google Scholar
• Pizarro T. T., Cominelli F. Cytokine therapy for Crohn's disease: Advances in translational research. Annu. Rev. Med. 2007; 58: 433–444
   PubMed Web of Science ®Google Scholar
• Pizarro T. T., Arseneau K. O., Bamias G., Cominelli F. Mouse models for the study of Crohn's disease. Trends Mol. Med. 2003; 9: 218–222
   PubMed Web of Science ®Google Scholar
• Sandborn W. J., Hanauer S. B. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 1999; 5: 119–133
   PubMed Web of Science ®Google Scholar
• Sandborn W. J., Targan S. R. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592–1608
   PubMed Web of Science ®Google Scholar
• Sands B. E. Inflammatory bowel disease: Past, present, and future. J. Gastroenterol. 2007; 42: 16–25
   PubMed Web of Science ®Google Scholar
• Smith J. P., Stock H., Bingaman S., Mauger D., Rogosnitzky M., Zagon I. S. Low-dose naltrexone therapy improves active Crohn's disease. Am. J. Gastroenterol. 2007; 102: 820–828
   PubMed Web of Science ®Google Scholar
• Strober W, Fuss I. J., Blumberg R. S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002; 20: 495–549
   PubMed Web of Science ®Google Scholar
• Targan S. R., Hanauer S. B., van Deventer S. J., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. Crohn's Disease cA2 Study Group. New Engl. J. Med. 1997; 337: 1029–1035
   PubMed Web of Science ®Google Scholar
• Tomassini N., Renaud F. L., Roy S., Loh H. H. Mu and delta receptors mediate morphine effects on phagocytosis by murine peritoneal macrophages. J. Neuroimmunol. 2003; 136: 9–16
   PubMed Web of Science ®Google Scholar
• Vujic V., Stanojevic S., Dimitrijevic M. Methionine-enkephalin stimulates hydrogen peroxide and nitric oxide production in rat peritoneal macrophages: Interaction of μ, δ, and κ opioid receptors. Neuroimmunomodulation 2004; 11: 392–403
   PubMed Web of Science ®Google Scholar
• Wang X., Seed B. A PCR primer bank for quantitative gene expression analysis. Nucl. Acids Res. 2003; 31: e154
   PubMed Web of Science ®Google Scholar
• Williams K. L., Fuller C. R., Dieleman L. A., DaCosta C. M., Haldeman K. M., Sartor R. B., Lund P. K. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that over-express growth hormone. Gastroenterology 2001; 120: 925–937
   PubMed Web of Science ®Google Scholar
• Zagon I. S., Wu Y., McLaughlin P. J. Opioid growth factor is present in human and mouse gastrointestinal tract and inhibits DNA synthesis. Am. J. Physiol. 1997; 272: R1094–R1104
   PubMedGoogle Scholar
• Zaitsev S. V., Sazanov L. A., Koshkin A. A., Sud'ina G. F., Varfolomeev S. D. Respiratory burst inhibition in human neutrophils by ultra-low doses of [D-Ala2]-methionine enkephalinamide. FEBS Lett. 1991; 291: 84–86
   PubMedGoogle Scholar
• Zurawski G., Benedik M., Kamb B. J., Abrams J. S., Zurawski S. M., Lee F. D. Activation of mouse T-helper cells induces abundant pre-proenkephalin mRNA synthesis. Science 1986; 232: 772–775
   PubMed Web of Science ®Google Scholar